Vittoria Mattioni Marchetti
Overview
Explore the profile of Vittoria Mattioni Marchetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mattioni Marchetti V, Venturelli I, Cassetti T, Meschiari M, Migliavacca R, Bitar I
Front Cell Infect Microbiol
. 2024 Sep;
14:1447933.
PMID: 39247055
Fosfomycin (FOS) is an effective antibiotic against multidrug-resistant , but its effectiveness is reducing. Little is known on the current prevalence of FosA enzymes in low-risk pathogens, such as ....
2.
Chudejova K, Caltagirone M, Mattioni Marchetti V, Rezzani A, Navarra A, Bitar I
Euro Surveill
. 2024 May;
29(21).
PMID: 38785090
Fosfomycin-resistant FosA8-producing are uncommon strains with extremely low incidence in Europe, based on only three reports in the literature. We detected FosA8-producing ST131 in clinical isolates from two patients admitted...
3.
Mattioni Marchetti V, Kuka A, Piazza A, Gaiarsa S, Merla C, Sottosanti M, et al.
Sci Rep
. 2024 May;
14(1):9987.
PMID: 38693199
No abstract available.
4.
Piazza A, Mattioni Marchetti V, Bielli A, Batisti Biffignandi G, Piscopiello F, Giudici R, et al.
J Microbiol Immunol Infect
. 2024 Apr;
57(3):457-469.
PMID: 38584042
Introduction: Aim of the study was the molecular characterization of 21 ceftazidime/avibactam resistant (CZA-R) Klebsiella pneumoniae strains, collected in the period October 2021-March 2022 from an Intensive Care COVID Unit...
5.
Mattioni Marchetti V, Kuka A, Piazza A, Gaiarsa S, Merla C, Sottosanti M, et al.
Sci Rep
. 2024 Mar;
14(1):6220.
PMID: 38486043
Enterobacter asburiae, member of the Enterobacter cloacae complex (ECC) group, shows an increasing clinical relevance being responsible for infections like pneumonia, urinary tract infections and septicemia. The aim of the...
6.
Piazza A, Corbella M, Mattioni Marchetti V, Merla C, Mileto I, Kuka A, et al.
Euro Surveill
. 2024 Feb;
29(8).
PMID: 38390649
The dissemination of carbapenemase-producing although still at low level, should be continuously monitored. OXA-244 is emerging in Europe, mainly in . In Italy, this carbapenemase was reported from an environmental...
7.
Mattioni Marchetti V, Hrabak J, Bitar I
Front Cell Infect Microbiol
. 2023 Jul;
13:1178547.
PMID: 37469601
Antimicrobial resistance is well-known to be a global health and development threat. Due to the decrease of effective antimicrobials, re-evaluation in clinical practice of old antibiotics, as fosfomycin (FOS), have...
8.
Silva Nodari C, Opazo-Capurro A, Castillo-Ramirez S, Mattioni Marchetti V
Front Cell Infect Microbiol
. 2023 Apr;
13:1180510.
PMID: 37009500
No abstract available.
9.
Bitar I, Papagiannitsis C, Kraftova L, Mattioni Marchetti V, Petinaki E, Finianos M, et al.
Front Microbiol
. 2023 Jan;
13:993240.
PMID: 36687644
Background: VIM metallo-β-lactamases are enzymes characterized by the ability to hydrolyze all β-lactams. Usually, -like genes are carried by class 1 integrons. In the Czech Republic, only sporadic cases of...
10.
OXA-244-Producing ST131 From Surface and Groundwaters of Pavia Urban Area (Po Plain, Northern Italy)
AbuAlshaar A, Piazza A, Mercato A, Marchesini F, Mattioni Marchetti V, Bitar I, et al.
Front Microbiol
. 2022 Jun;
13:920319.
PMID: 35756019
The study aimed to investigate (i) the occurrence of third-generation cephalosporins and/or carbapenems non-sensitive in Pavia surface and groundwaters, (ii) their resistance determinants, and (iii) the clonal features of the...